DiaMedica Therapeutics (DMAC) announced its upcoming addition as a member of the US small-cap Russell 2000 and Russell 3000 Indexes, effective after the U.S. market closes on June 27. President and CEO Rick Pauls stated the inclusion marks an important milestone, enhancing visibility among the broader investment community. DiaMedica also noted it recently hosted a preeclampsia webinar and plans to announce top-line Phase 2 results for DM199 by mid-July.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DMAC:
- Promising Potential of Diamedica Therapeutics’ DM199 in Preeclampsia Treatment Drives Buy Rating
- DiaMedica Therapeutics’ Earnings Call Highlights Progress and Stability
- DiaMedica Elects Directors at Annual Meeting
- DiaMedica Therapeutics Reports Q1 2025 Financials and Trial Progress
- DiaMedica Therapeutics Reports Q1 2025 Financial Results and Clinical Progress